EUCTR2005-005405-37-BE进行中(未招募)不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age =18 years
- •2.Cytologically or histologically confirmed diagnosis of: stage IIIB or IV NSCLC receiving first line myelosuppressive chemotherapy (without planned concurrent thoracic radiotherapy)
- •3.Hemoglobin =11 g/dL (110 g/L) at screening visit
- •4.Myelosuppressive chemotherapy scheduled for at least 9 weeks from first planned dose of study medication
- •5.Life expectancy =6 months
- •6.ECOG performance status 0-2
- •7.Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Transfusion of red blood cells during the 4 weeks (28 days) prior to the first planned dose of study medication
- •2.Radiation therapy to >25% of bone marrow containing areas within the 2 weeks (14 days) prior to the first planned dose of study medication or planned thoracic radiotherapy to be administered concurrently during the study
- •3.Prior diagnosis of myeloid malignancy
- •4.Known primary or metastatic malignancy of the central nervous system
- •5.Stage II hypertension (stage II hypertension is defined as SBP > or = 160 mm Hg or DBP > or = 100 mm Hg
- •6. AST/ALT > 5x ULN
- •7.Iron deficiency defined as both transferrin saturation <20% and serum ferritin <100 ng/mL (224 pmol/L)
- •8.Grade 3/4 thrombocytopenia: platelet count <50 x 109/L
- •9.Known uncorrected vitamin B12 or folic acid deficiency
- •10.Prior diagnosis of primary red cell disorders which cause anemia (i.e., hemoglobinopathy, PRCA)
- •11.Significant hemolysis requiring medical intervention
- •12.Acute or chronic bleeding requiring therapy within 3 months prior to planned start of study medication (e.g. patients with anemia caused by gastrointestinal bleeding)
- •13.Acute infection requiring parenteral antibiotic therapy
- •14.History of seizures within the previous 6 months
- •15.Pregnancy or breastfeeding
- •16.Women of child bearing potential without effective contraception
研究者
相似试验
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapyEUCTR2005-005405-37-EEF. Hoffmann-La Roche Ltd.200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV nonsmall cell lung cancer receiving first line myelosuppressive chemotherapy - NDAnemia in cancer patients receiving chemotherapyMedDRA version: 6.1Level: PTClassification code 10061873EUCTR2005-005405-37-ITROCHE200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapyEUCTR2005-005405-37-FIF. Hoffmann-La Roche Ltd.200
进行中(未招募)
1 期
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyEUCTR2005-005405-37-CZF. Hoffmann-La Roche Ltd.200
进行中(未招募)
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapyEUCTR2005-005405-37-ATF. Hoffmann-La Roche Ltd.200
